JP2003523338A - 抗腫瘍活性を有するオキシ−及びアミノ−置換テトラヒドロフリル誘導体 - Google Patents

抗腫瘍活性を有するオキシ−及びアミノ−置換テトラヒドロフリル誘導体

Info

Publication number
JP2003523338A
JP2003523338A JP2001560195A JP2001560195A JP2003523338A JP 2003523338 A JP2003523338 A JP 2003523338A JP 2001560195 A JP2001560195 A JP 2001560195A JP 2001560195 A JP2001560195 A JP 2001560195A JP 2003523338 A JP2003523338 A JP 2003523338A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
independently
alkyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001560195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003523338A5 (enExample
Inventor
辰雄 比嘉
淳一 田中
ドロレス・ガルシア・グラヴァロス
Original Assignee
ファルマ・マール・ソシエダード・アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0003629A external-priority patent/GB0003629D0/en
Priority claimed from GB0021774A external-priority patent/GB0021774D0/en
Application filed by ファルマ・マール・ソシエダード・アノニマ filed Critical ファルマ・マール・ソシエダード・アノニマ
Publication of JP2003523338A publication Critical patent/JP2003523338A/ja
Publication of JP2003523338A5 publication Critical patent/JP2003523338A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
JP2001560195A 2000-02-16 2001-02-16 抗腫瘍活性を有するオキシ−及びアミノ−置換テトラヒドロフリル誘導体 Pending JP2003523338A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0003629A GB0003629D0 (en) 2000-02-16 2000-02-16 Antitumour agent
GB0003629.3 2000-02-16
GB0021774.5 2000-09-05
GB0021774A GB0021774D0 (en) 2000-09-05 2000-09-05 Anti-tumour compound
PCT/GB2001/000655 WO2001060810A1 (en) 2000-02-16 2001-02-16 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity

Publications (2)

Publication Number Publication Date
JP2003523338A true JP2003523338A (ja) 2003-08-05
JP2003523338A5 JP2003523338A5 (enExample) 2008-03-27

Family

ID=26243662

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001560195A Pending JP2003523338A (ja) 2000-02-16 2001-02-16 抗腫瘍活性を有するオキシ−及びアミノ−置換テトラヒドロフリル誘導体

Country Status (17)

Country Link
US (1) US6864283B2 (enExample)
EP (1) EP1255746B1 (enExample)
JP (1) JP2003523338A (enExample)
KR (1) KR20020092958A (enExample)
CN (1) CN1318409C (enExample)
AT (1) ATE316524T1 (enExample)
AU (2) AU2001233873B2 (enExample)
BR (1) BR0108448A (enExample)
CA (1) CA2400612C (enExample)
CZ (1) CZ20022791A3 (enExample)
DE (1) DE60116855T2 (enExample)
ES (1) ES2256199T3 (enExample)
IL (1) IL151241A (enExample)
MX (1) MXPA02007995A (enExample)
PL (1) PL357193A1 (enExample)
RU (1) RU2002124591A (enExample)
WO (1) WO2001060810A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001233873B2 (en) 2000-02-16 2006-03-02 Pharma Mar, S.A. Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
CN102229585A (zh) * 2011-04-26 2011-11-02 中国人民解放军第二军医大学 具有抗肿瘤活性的γ-丁内酯聚酮类化合物
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (en) * 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US6107520A (en) * 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
AU2001233873B2 (en) 2000-02-16 2006-03-02 Pharma Mar, S.A. Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity

Also Published As

Publication number Publication date
EP1255746A1 (en) 2002-11-13
WO2001060810A1 (en) 2001-08-23
US20030092738A1 (en) 2003-05-15
ES2256199T3 (es) 2006-07-16
AU3387301A (en) 2001-08-27
AU2001233873B2 (en) 2006-03-02
RU2002124591A (ru) 2004-01-10
DE60116855D1 (de) 2006-04-13
CA2400612A1 (en) 2001-08-23
CA2400612C (en) 2010-05-11
CN1423642A (zh) 2003-06-11
US6864283B2 (en) 2005-03-08
KR20020092958A (ko) 2002-12-12
DE60116855T2 (de) 2006-09-14
BR0108448A (pt) 2003-04-01
MXPA02007995A (es) 2003-05-23
CZ20022791A3 (cs) 2003-02-12
WO2001060810B1 (en) 2001-11-29
EP1255746B1 (en) 2006-01-25
PL357193A1 (en) 2004-07-26
CN1318409C (zh) 2007-05-30
ATE316524T1 (de) 2006-02-15
IL151241A (en) 2006-10-31

Similar Documents

Publication Publication Date Title
US10562864B2 (en) Chemical modulators of immune checkpoints and therapeutic use
TW202116778A (zh) 作為治療劑之細胞毒素之肽結合物
JP2003509386A (ja) タキサン・プロドラッグ
CN106132968B (zh) 一种用于防止或治疗癌症的抑制溴结构域的化合物及含有该化合物的药物组合物
CN104812388A (zh) 新型化合物、其合成及其用途
CN106572991A (zh) 用于克服铂耐受性的德克萨卟啉‑pt(iv)缀合物及组合物
EP3470410B1 (en) Crystalline form of compound suppressing protein kinase activity, and application thereof
CN1964979B (zh) 新颖的水溶性前药
WO2024153185A1 (zh) 包含bcl-2家族蛋白降解剂的抗体药物偶联物及其制备方法和用途
JP2004536132A (ja) 新規なｅｔ−７４３の抗腫瘍性誘導体
US20230416331A1 (en) Peptide conjugates of peptidic tubulin inhibitors as therapeutics
CN106715411B (zh) 苯并二氮杂*衍生物
CN103965175A (zh) 4-(取代苯氨基)喹唑啉类化合物、其制备方法及应用
CN113439084B (zh) 倍癌霉素类似物
CA2400612C (en) Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
JP2002526540A (ja) 細胞毒性アルカロイド類（ハリツリン）
JP2000502351A (ja) 医薬化合物
CN101463029B (zh) 紫杉烷衍生物及其制法和用途
JP2024526865A (ja) 腎癌の標的治療のための新規化合物及び組成物
AU2001233873A1 (en) Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
WO2016206138A1 (zh) 组蛋白去乙酰化酶抑制剂及其制备方法和应用
KR19990034285A (ko) 항암활성을 갖는 육두구 추출물
US10576092B1 (en) Doxorubicin derivatives and uses thereof
CN119306762A (zh) 基于不稳定的氨基酸的新型癌症protac药物化合物的设计与应用
JP2003531904A (ja) ストロノキシド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111206